Reliance Life Sciences darbepoetin alfa
Darbepoetin alfa biosimilar developed by Reliance Life Sciences. Reference product Aranesp (Nesp in Japan).
Brands by market: Brand not published by CDSCO (India) ยท Commercial partner or holder: Reliance Life Sciences
FDAnot listed
EMAnot listed
PMDAnot listed
HCnot listed
CDSCOJun 2016permitted
EDEnot listed
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union
Not listed by EMA.
PMDA
Japan
Not listed by PMDA.
HC
Canada
Not listed by HC.
CDSCO
India
Central Drugs Standard Control OrganisationApprovedBrand
Not published by CDSCO (INN only)
Holder or applicant
Reliance Life Sciences Pvt Ltd
Pathway
Similar Biologic, manufacture and marketing permission
Approved
Jun 2016
Application or permission
MF-91/2016; BULK-92/2016
Indications as licensed
Anaemia of chronic kidney disease; chemotherapy-induced anaemia in non-myeloid malignancy
Presentations
Injection
Source
S014
EDE
United Arab Emirates
Not listed by EDE.
Chronology
- CDSCOJun 2016CDSCO permission granted
Sources
S014CDSCO, permissions granted in Form 46 and 46A, to 2019 Primary (regulator)
Planning darbepoetin alfa biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.